|
🐜
|
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
228 auth.
L. Paz-Ares,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
L. Havel,
...
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
N. Shire,
Haiyi Jiang,
J. Goldman,
E. Batagelj,
Ignacio Casarini,
A. V. Pastor,
S. Sena,
J. Zarbá,
O. Burghuber,
S. Hartl,
B. Lamprecht,
M. Studnicka,
L. Schlittler,
Fabricio Augusto Martinelli de Oliveira,
A. Calabrich,
G. Girotto,
P. Reis,
Carlo Gorini,
Peo Rafael Martins De Marchi,
C. Baldotto,
C. Sette,
M. Zukin,
A. Dudov,
R. Ilieva,
K. Koynov,
R. Krasteva,
I. Tonev,
S. Valev,
V. Venkova,
M. Bi,
Chengshui Chen,
Yuan Chen,
Zhendong Chen,
J. Fang,
Jifeng Feng,
Zhigang Han,
Jie Hu,
Yi Hu,
Wei Li,
Zongan Liang,
Zhong Lin,
R. Ma,
Shenglin Ma,
K. Nan,
Y. Shu,
Kai Wang,
Mengzhao Wang,
Gang Wu,
N. Yang,
Zhi-Xiong Yang,
He-long Zhang,
Wei Zhang,
Jun Zhao,
Yanqiu Zhao,
Caicun Zhou,
Jianying Zhou,
Xiang-dong Zhou,
V. Kolek,
L. Koubková,
J. Roubec,
J. Skřičková,
M. Zemanova,
C. Chouaid,
W. Hilgers,
H. Léna,
D. Moro-Sibilot,
G. Robinet,
P. Souquet,
J. Alt,
H. Bischoff,
C. Grohé,
E. Laack,
S. Lang,
J. Panse,
C. Schulz,
K. Bogos,
E. Csánky,
Anea Fülöp,
Z. Horváth,
Judit Kósa,
I. Laczó,
G. Pajkos,
Z. Pápai,
Zsolt Pápai Székely,
V. Sárosi,
A. Somfay,
É. Ezer,
Anás Telekes,
J. Bar,
M. Gottfried,
N. Heching,
Alona Zer Kuch,
R. Bartolucci,
A. Bettini,
A. Delmonte,
M. Garassino,
M. Minelli,
F. Roila,
S. Atagi,
K. Azuma,
H. Goto,
K. Goto,
Yu Hara,
H. Hayashi,
T. Hida,
Kenya Kanazawa,
S. Kanda,
Y. H. Kim,
S. Kuyama,
T. Maeda,
M. Morise,
Y. Nakahara,
M. Nishio,
N. Nogami,
I. Okamoto,
H. Saito,
M. Shinoda,
S. Umemura,
T. Yoshida,
N. Claessens,
R. Cornelissen,
Lizza Heniks,
Jeroen Hiltermann,
E. Smit,
A. J. S. D. Brekel,
D. Kowalski,
S. Mańdziuk,
Robert Mróz,
M. Wojtukiewicz,
T. Ciuleanu,
D. Ganea,
A. Ungureanu,
A. Luft,
V. Moiseenko,
D. Sakaeva,
A. Smolin,
Alexander Vasilyev,
L. Vladimirova,
Igor Anasina,
J. Chovanec,
P. Demo,
R. Godal,
P. Kasan,
M. Stresko,
M. Urda,
E. Cho,
Joo‐Hang Kim,
Sang-We Kim,
Gyeong-Won Lee,
Jong-Seok Lee,
K. Lee,
K. Lee,
Yun-Gyoo Lee,
M. Molla,
M. D. Gómez,
J. I. D. Mingorance,
D. Casado,
M. L. Brea,
M. M. Tarruella,
T. M. Bueno,
A. N. Mendivil,
Luis Paz-Ares Rodríguez,
S. P. Aix,
M. Campelo,
G. Chang,
Yen-Hsun Chen,
C. Chiu,
T. Hsia,
Kang-Yun Lee,
Chien-Te Li,
Chin-Chou Wang,
Yu-Feng Wei,
Shang‐Yin Wu,
A. Alacacıoğlu,
I. Çiçin,
A. Demirkazık,
M. Erman,
T. Göksel,
H. Adamchuk,
O. Kolesnik,
A. Kryzhanivska,
Y. Ostapenko,
S. Shevnia,
Y. Shparyk,
G. Ursol,
N. Voitko,
I. Vynnychenko,
S. Babu,
A. Chiang,
W. Chua,
S. Dakhil,
A. Dowlati,
Basir Haque,
Rodney Jamil,
J. Knoble,
Shailena Lakhanpal,
Kailhong Mi,
P. Nikolinakos,
S. Powell,
H. Ross,
E. Schaefer,
J. Schneider,
Joseph E. Spahr,
D. Spigel,
J. Stilwill,
C. Sumey,
Michael Williamson
|
10 |
2019 |
10
🐜
|
|
🐜
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
25 auth.
J. Goldman,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
M. Garassino,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
...
L. Havel,
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
P. Thiyagarajah,
Haiyi Jiang,
L. Paz-Ares
|
8 |
2020 |
8
🐜
|
|
🐜
|
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
21 auth.
L. Paz-Ares,
Y. Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
M. Garassino,
...
O. Voitko,
A. Poltoratskiy,
E. Musso,
L. Havel,
I. Bondarenko,
G. Losonczy,
N. Conev,
H. Mann,
T. Dalvi,
H. Jiang,
J. Goldman
|
7 |
2022 |
7
🐜
|
|
🐜
|
PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
20 auth.
L. Paz-Ares,
J. Goldman,
M. Garassino,
M. Dvorkin,
D. Trukhin,
G. Statsenko,
K. Hotta,
J. H. Ji,
M. Hochmair,
O. Voitko,
...
L. Havel,
A. Poltoratskiy,
G. Losonczy,
N. Reinmuth,
Y. Shrestha,
N. Patel,
H. Mann,
Haiyi Jiang,
M. Ozguroglu,
Y. Chen
|
5 |
2019 |
5
🐜
|
|
🐜
|
Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
19 auth.
L. Paz-Ares,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
...
O. Voitko,
A. Poltoratskiy,
F. Verderame,
L. Havel,
I. Bondarenko,
J. Armstrong,
N. Byrne,
Haiyi Jiang,
J. Goldman
|
5 |
2020 |
5
🐜
|
|
🐜
|
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
20 auth.
J. Goldman,
M. Garassino,
Yuanbin Chen,
M. Özgüroğlu,
M. Dvorkin,
D. Trukhin,
G. Statsenko,
K. Hotta,
J. Ji,
M. Hochmair,
...
O. Voitko,
L. Havel,
A. Poltoratskiy,
G. Losonczy,
N. Reinmuth,
N. Patel,
Peter J. Laud,
N. Shire,
Haiyi Jiang,
L. Paz-Ares
|
4 |
2020 |
4
🐜
|
|
🐜
|
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
17 auth.
Yuanbin Chen,
L. Paz-Ares,
N. Reinmuth,
M. Garassino,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
F. Verderame,
L. Havel,
G. Losonczy,
...
N. Conev,
K. Hotta,
J. Ji,
S. Spencer,
T. Dalvi,
Haiyi Jiang,
J. Goldman
|
4 |
2022 |
4
🐜
|
|
🐜
|
LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
20 auth.
J. Goldman,
M. Garassino,
Yuh-Min Chen,
N. Reinmuth,
K. Hotta,
A. Poltoratskiy,
D. Trukhin,
M. Hochmair,
M. Ozguroglu,
J. Ji,
...
G. Statsenko,
O. Voitko,
N. Conev,
I. Bondarenko,
S. Spencer,
M. Xie,
S. Jones,
A. Franks,
Y. Shrestha,
L. Paz-Ares
|
4 |
2020 |
4
🐜
|
|
🐜
|
Five‐year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry
13 auth.
I. Tsimafeyeu,
Tatiana Zolotareva,
S. Varlamov,
R. Zukov,
V. Petkau,
M. Mazhbich,
G. Statsenko,
S. Safina,
I. Zaitsev,
D. Sakaeva,
...
A. Popov,
P. Borisov,
L. Vladimirova
|
4 |
2017 |
4
🐜
|
|
🐜
|
PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
23 auth.
L. Paz-Ares,
Y. Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Ozguroglu,
J. H. Ji,
O. Voitko,
...
A. Poltoratskiy,
S. Ponce,
F. Verderame,
L. Havel,
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
N. Shire,
Haiyi Jiang,
J. Goldman
|
4 |
2019 |
4
🐜
|
|
🐜
|
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
22 auth.
L. Paz-Ares,
M. Garassino,
Yuanbin Chen,
Niels Reinmuth,
K. Hotta,
A. Poltoratskiy,
D. Trukhin,
M. Hochmair,
M. Özgüroğlu,
Jun Ho Ji,
...
G. Statsenko,
Nikolay Conev,
Igor Bondarenko,
L. Havel,
G. Losonczy,
Mingchao Xie,
Zhongwu Lai,
Nadia Godin-Heymann,
Helen Mann,
Haiyi Jiang,
Y. Shrestha,
J. Goldman
|
3 |
2023 |
3
🐜
|
